Sunesis reports subgroup data for Qinprezo
Sunesis Pharmaceutics Inc. (NASDAQ:SNSS) gained $0.08 to $2.62 on Friday after announcing results from a predefined subgroup analysis of its 711-patient Phase III VALOR study of Qinprezo vosaroxin to treat acute myelogenous leukemia (AML). Last year, Qinprezo missed the study's primary endpoint of improving overall survival (OS).
In an analysis presented Friday at the European Hematology Association meeting in Vienna, a 364-patient subgroup of patients 60 or older with refractory and early relapse disease receiving Qinprezo plus cytarabine had a median OS of 6.5 months vs. 3.9 months for patients receiving placebo plus cytarabine (HR=0.69, p=0.0008). Leukemia-free survival (LFS) was 9.7 months for the Qinprezo group vs. 5.5 months for control (HR=0.50, p=0.0424), while event-free survival (EFS) was 1.7 months for Qinprezo vs. 1.3 months for control (HR=0.59, p<0.0001). ...